Christenson, Jessica L.
Butterfield, Kiel T.
Spoelstra, Nicole S.
Norris, John D.
Josan, Jatinder S.
Pollock, Julie A.
McDonnell, Donald P.
Katzenellenbogen, Benita S.
Katzenellenbogen, John A.
Richer, Jennifer K.
Funding for this research was provided by:
National Cancer Institute (R01 CA187733-01A1)
U.S. Department of Defense (W81XWH-10-1-0179, W81XWH-15-1)
Breast Cancer Research Foundation
National Institutes of Health (T32 CA190216-01A1)
Article History
Received: 19 December 2016
Accepted: 27 January 2017
First Online: 13 February 2017
Compliance with Ethical Standards
:
: This study was funded by a National Institute of Health R01 CA187733-01A1 to JKR; NIH NRSA T32 CA190216-01A1 postdoctoral fellowship to JLC; US Army Synergistic Idea Development Awards W81XWH-10-1-0179 and W81XWH-15-1 to JAK, JSJ, JAP, JN, and DPMcD; Breast Cancer Research Foundation grant to BSK; and enzalutamide was provided by Astellas, Inc. and Medivation, Inc. (Medivation, Inc. was acquired by Pfizer, Inc. in September 2016).
: The authors declare that they have no conflict of interest.
: This article does not contain any studies with human participants performed by any of the authors. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
Free to read: This content has been made available to all.